Ammirati Adriano Luiz, Dalboni Maria Aparecida, Cendoroglo Miguel, Draibe Sérgio Antonio, Santos Raul D, Miname Márcio, Canziani Maria Eugênia F
Nephrology Division, Federal University of São Paulo, 282 Pedro de Toledo Street, São Paulo 04039-000, Brazil.
Perit Dial Int. 2007 May-Jun;27(3):340-6.
Progression of coronary artery calcification (CAC) has been described in hemodialysis patients, and severe CAC has been associated with the occurrence of cardiovascular events in this population. Little information is available regarding peritoneal patients.
To prospectively evaluate peritoneal dialysis patients in order to identify the variables associated with the rate of CAC progression, as well as to determine the impact that baseline CAC has on clinical outcomes over a 1-year follow-up period.
Using multislice coronary tomography, calcium scores were estimated at baseline and after 12 months in 49 peritoneal dialysis patients. Patients with and without CAC progression were compared with respect to clinical characteristics and biochemical variables, including lipid profile, parameters of mineral metabolism, and markers of inflammation. Cardiovascular events, hospitalizations, and all-cause mortality were recorded.
At baseline, 29 patients (59%) presented CAC and a median calcium score of 234.7 (range 10.3-2351) Agatston units. Progression of CAC was observed in 13 patients (43%) who, in comparison with those presenting no CAC progression, were older, presented higher baseline calcium scores, and had higher mean glucose levels, lower mean high density lipoprotein cholesterol levels, and more months using low calcium peritoneal solution. We also observed a trend toward more often presenting with a history of hypertension, exhibiting more hyperphosphatemic and hyperglycemic events, and having lower albumin levels. In multiple logistic regression, only baseline calcium score was independently associated with progression of CAC. A shorter cardiovascular event-free time and a trend toward lower survival rates were observed in the group with CAC. Hospitalization event-free time did not differ between the groups.
Determining CAC provides important prognostic data in peritoneal dialysis patients. Baseline calcium score and disturbances in glucose, mineral, and lipid metabolism were indicative of higher risk of CAC progression in this population.
血液透析患者中已出现冠状动脉钙化(CAC)进展的情况,且严重的CAC与该人群心血管事件的发生有关。关于腹膜透析患者的相关信息较少。
前瞻性评估腹膜透析患者,以确定与CAC进展率相关的变量,并确定基线CAC在1年随访期内对临床结局的影响。
对49例腹膜透析患者在基线时和12个月后使用多层冠状动脉断层扫描估算钙评分。比较有和没有CAC进展的患者的临床特征和生化变量,包括血脂谱、矿物质代谢参数和炎症标志物。记录心血管事件、住院情况和全因死亡率。
基线时,29例患者(59%)出现CAC,中位钙评分为234.7(范围10.3 - 2351)阿加斯顿单位。13例患者(43%)观察到CAC进展,与未出现CAC进展的患者相比,这些患者年龄更大,基线钙评分更高,平均血糖水平更高,平均高密度脂蛋白胆固醇水平更低,使用低钙腹膜透析液的时间更长。我们还观察到一种趋势,即更常出现高血压病史,出现更多高磷血症和高血糖事件,且白蛋白水平更低。在多因素逻辑回归中,只有基线钙评分与CAC进展独立相关。在有CAC的组中观察到无心血管事件时间较短且生存率有降低趋势。两组间无住院事件时间无差异。
测定CAC可为腹膜透析患者提供重要的预后数据。基线钙评分以及葡萄糖、矿物质和脂质代谢紊乱表明该人群中CAC进展风险较高。